Related Experiment Video
Updated: Jun 27, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers
Alexia Piperidou1, Panagiota-Efstathia Nikolaou2,3, Despina Fotiou4
1Department of Hematology and Bone Marrow Transplantation, Medical School, National and Kapodistrian University of Athens, General Hospital of Athens "Laikon", 11527 Athens, Greece.
International Journal of Molecular Sciences
|June 26, 2026
Summary
Venous thrombosis is common in lymphoma patients. New biomarkers combined with clinical factors may improve personalized risk prediction and prevention strategies for this complication.
Area of Science:
- Hematology
- Oncology
- Vascular Medicine
Background:
- Venous thrombosis is a significant complication in lymphoma patients, increasing morbidity and mortality.
- Existing cancer-associated thrombosis (CAT) prediction tools are suboptimal for lymphoma due to disease heterogeneity.
- Lymphoma-associated thrombosis results from multifactorial mechanisms including clinical, tumor, inflammatory, endothelial, and therapy-induced factors.
Purpose of the Study:
- To review current knowledge on thrombotic risk assessment in lymphoma.
- To highlight the potential of novel biomarkers for improved thrombosis prediction.
- To emphasize the need for personalized thrombosis risk stratification in lymphoma management.
Main Methods:
- Review of current literature on venous thrombosis in lymphoma.
- Evaluation of traditional predictive tools like the ThroLy score.
- Assessment of emerging biomarkers (D-dimer, microparticles, cytokines) for risk prediction.
Main Results:
- The ThroLy score shows improved predictive value over general CAT models but has limitations.
- Novel biomarkers show promise for enhancing risk assessment accuracy.
- Integrative approaches combining clinical variables and biomarkers may offer dynamic, individualized risk prediction.
Conclusions:
- Current risk assessment for venous thrombosis in lymphoma is limited.
- Novel biomarkers are crucial for developing precise, personalized thromboprophylactic strategies.
- Further research is needed to integrate biomarkers into clinical practice for lymphoma patients.
Related Concept Videos
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...